Annovis Bio Shares Rise After Positive Trial Data for Buntanetap

Dow Jones

7小时前

By Chris Wack

Annovis Bio shares were 43% higher, at $3.33, after the company reported positive results from a Phase 3 trial for buntanetap.

The late-stage clinical drug-platform company on Monday said the new data demonstrated a positive impact of amyloid copathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap.

The Malvern, Pa., company said that in its Phase 3 study in early Parkinson's patients, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia.

Further analysis revealed that about 25% of patients exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which Annovis said was counteracted and reversed by buntanetap.

Buntanetap treatment also led to significant cognitive improvement in Parkinson's patients with amyloid copathology.

Write to Chris Wack at chris.wack@wsj.com

(END) Dow Jones Newswires

November 17, 2025 12:43 ET (17:43 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2584689673"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2584689673\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2584689673?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-18 01:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2584689673","market":"other","top_or_hot":-1,"title":"Annovis Bio Shares Rise After Positive Trial Data for Buntanetap","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ANVS\">Annovis Bio</a> shares were 43% higher, at $3.33, after the company reported positive results from a Phase 3 trial for buntanetap. \n</p>\n<p>\n  The late-stage clinical drug-platform company on Monday said the new data demonstrated a positive impact of amyloid copathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap. \n</p>\n<p>\n  The Malvern, Pa., company said that in its Phase 3 study in early Parkinson's patients, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia. \n</p>\n<p>\n  Further analysis revealed that about 25% of patients exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which Annovis said was counteracted and reversed by buntanetap. \n</p>\n<p>\n  Buntanetap treatment also led to significant cognitive improvement in Parkinson's patients with amyloid copathology. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 12:43 ET (17:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Annovis Bio Shares Rise After Positive Trial Data for Buntanetap</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAnnovis Bio Shares Rise After Positive Trial Data for Buntanetap\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-11-18 01:43</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Chris Wack \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  <a href=\"https://laohu8.com/S/ANVS\">Annovis Bio</a> shares were 43% higher, at $3.33, after the company reported positive results from a Phase 3 trial for buntanetap. \n</p>\n<p>\n  The late-stage clinical drug-platform company on Monday said the new data demonstrated a positive impact of amyloid copathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap. \n</p>\n<p>\n  The Malvern, Pa., company said that in its Phase 3 study in early Parkinson's patients, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia. \n</p>\n<p>\n  Further analysis revealed that about 25% of patients exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which Annovis said was counteracted and reversed by buntanetap. \n</p>\n<p>\n  Buntanetap treatment also led to significant cognitive improvement in Parkinson's patients with amyloid copathology. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Chris Wack at chris.wack@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  November 17, 2025 12:43 ET (17:43 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"ANVS","symbol_name":"Annovis Bio, Inc.","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2584689673","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2584689673","pubTimestamp":1763401380,"columns":[{"name":"行业数据","id":30,"label_key":"dataReport"}],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Annovis Bio shares were 43% higher, at $3.33, after the company reported positive results from a Phase 3 trial for buntanetap.The late-stage clinical drug-platform company on Monday said the new data demonstrated a positive impact of amyloid copathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap.The Malvern, Pa., company said that in its Phase 3 study in early Parkinson's patients, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia.Further analysis revealed that about 25% of patients exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which Annovis said was counteracted and reversed by buntanetap.Buntanetap treatment also led to significant cognitive improvement in Parkinson's patients with amyloid copathology.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"ANVS":"Annovis Bio, Inc.","BK4139":"生物科技"},"translate_title":"Buntanetap试验数据积极后，Annovis Bio股价上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ANVS":1.5},"content_text":"By Chris Wack \n\n\n \n\n\nAnnovis Bio shares were 43% higher, at $3.33, after the company reported positive results from a Phase 3 trial for buntanetap. \n\n\n  The late-stage clinical drug-platform company on Monday said the new data demonstrated a positive impact of amyloid copathology on cognitive outcomes in Parkinson's patients and the therapeutic efficacy of buntanetap. \n\n\n  The Malvern, Pa., company said that in its Phase 3 study in early Parkinson's patients, buntanetap halted cognitive decline across the overall patient population, with the greatest improvement observed in those with mild dementia. \n\n\n  Further analysis revealed that about 25% of patients exhibited amyloid co-pathology and experienced more pronounced cognitive decline over the course of the study, which Annovis said was counteracted and reversed by buntanetap. \n\n\n  Buntanetap treatment also led to significant cognitive improvement in Parkinson's patients with amyloid copathology. \n\n\n \n\n\n  Write to Chris Wack at chris.wack@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 17, 2025 12:43 ET (17:43 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}